Elanco Animal Health CFO Departs; Interim Appointed

Ticker: ELAN · Form: 8-K · Filed: 2025-05-28T00:00:00.000Z

Sentiment: neutral

Topics: management-change, cfo-departure, interim-appointment

Related Tickers: ELAN

TL;DR

Elanco's CFO, Todd Young, is out. Oliver Godres is interim CFO. Search for permanent replacement underway.

AI Summary

Elanco Animal Health Incorporated announced on May 21, 2025, the departure of its Chief Financial Officer, Todd M. Young. The company has appointed Oliver G. Godres as the interim CFO. This change is effective immediately, and the company has initiated a search for a permanent CFO.

Why It Matters

A sudden departure of a CFO can signal internal challenges or strategic shifts, potentially impacting investor confidence and the company's financial direction.

Risk Assessment

Risk Level: medium — The departure of a CFO, especially without immediate permanent replacement, can create uncertainty regarding financial strategy and leadership stability.

Key Players & Entities

FAQ

Who is the new interim Chief Financial Officer for Elanco Animal Health?

Oliver G. Godres has been appointed as the interim Chief Financial Officer.

When was the departure of the previous CFO effective?

The departure of Todd M. Young was effective May 21, 2025.

Has Elanco Animal Health appointed a permanent CFO?

No, the company has initiated a search for a permanent CFO.

What is Elanco Animal Health's principal executive office address?

The address is 2500 Innovation Way, Greenfield, Indiana 46140.

What is the SEC file number for Elanco Animal Health?

The SEC file number is 001-38661.

From the Filing

0001104659-25-053305.txt : 20250528 0001104659-25-053305.hdr.sgml : 20250528 20250528073032 ACCESSION NUMBER: 0001104659-25-053305 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 19 CONFORMED PERIOD OF REPORT: 20250521 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250528 DATE AS OF CHANGE: 20250528 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elanco Animal Health Inc CENTRAL INDEX KEY: 0001739104 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 825497352 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38661 FILM NUMBER: 25991155 BUSINESS ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 BUSINESS PHONE: 877-352-6261 MAIL ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 8-K 1 tm2516292d1_8k.htm FORM 8-K false 0001739104 0001739104 2025-05-21 2025-05-21 0001739104 us-gaap:CommonStockMember 2025-05-21 2025-05-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES   SECURITIES AND EXCHANGE COMMISSION Washington , D. C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of Earliest Event Reported): May 21, 2025   Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter)   Indiana   001-38661   82-5497352 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   2500 Innovation Way Greenfield , Indiana (Address of principal executive offices)   46140 (Zip Code)   Registrant’s telephone number, including area code: ( 877 ) 352-6261   Not Applicable (Former Name or Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common stock, no par value   ELAN   New York Stock Exchange   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   ¨   Emerging growth company   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨           Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.   As discussed in the press release issued on May 28, 2025 by Elanco Animal Health Incorporated (the “Company”), the Company announced the appointment of Robert (Bob) VanHimbergen as Executive Vice President and Chief Financial Officer, effectiv

View on Read The Filing